| 英文摘要 |
Since 1970s, drugs are tested intrathecally for the evaluation of their analgesic as well as toxic effects. This starts a series of studies regarding spinal phar-macology and neurophysiology of certain drugs in pain management. Among them, the pharmacologic effects of opioids, including both (i- and 5- drugs, and y-aminoby- tyric acid (GABA) were demonstrated first and led to their further preclinical and clinical trials.1 Currently, certain receptors (ji- and 5- opioid, alpha-2, adenosine, GABAa, GABAb, benzodiazepine, TV-methyl-D-aspar- tate, a-amino-3-hydroxy-5-methyl-4-isoxazole-propion- ate, neurokinin-I, prostaglandin receptor, neurotrophin receptors, etc.), channels (voltage-sensitive calcium channels, potassium channels, etc), associated neuro-transmitters (agonists or antagonists), as well as regula-tory proteins (transcription, translation, phosphoration/ dephosphoration, etc.) have been identified to be active in modulating pain intensity in many different pain models.1'3 These findings do cast a light towards the solution of difficult clinical situations including intrac-table pain, inadequate efficacy, tolerance and adverse effects. However, since most of them are preclinical studies, much effort has to be done before any possible candidate can be applied clinically. |
本站僅提供期刊文獻檢索。
